Study of RMC-6236 in Patients With Advanced Solid Tumors Harboring Specific Mutations in RAS

Summary

Evaluate the safety and tolerability of RMC-6236 in adults with specific RAS mutant advanced solid tumors.

Interventions

• RMC-6236 · DRUG

  Oral Tablets

Published eligibility criteria

Verbatim from the registry. Only the site can decide how these apply to a specific patient.

Inclusion Criteria:

* Histologically confirmed advanced solid tumor with specific KRAS G12 mutations (dose escalation) or RAS mutations (dose optimization/expansion) identified through deoxyribonucleic acid (DNA) sequencing. PDAC with wild-type RAS (expansion).
* Treatment naive or have received prior standard therapy appropriate for tumor type and stage
* Have Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1
* Adequate organ function

Exclusion Criteria:

* Primary central nervous system (CNS) tumors
* Active, untreated brain metastases
* Known or suspected impairment of gastrointestinal function that may prohibit ability to swallow or absorb an oral medication
* History of any other unstable or clinically significant concurrent medical condition that would, in the opinion of the investigator, jeopardize the safety of a participant, impact their expected survival through the end of the study participation, and/or impact their ability to comply with the protocol prior/concomitant therapy

Other inclusion/exclusion criteria may apply.

Sites (21)

• UC Irvine/Chao Family Comprehensive Cancer Center, Orange, California · RECRUITING
• UCLA, Santa Monica, California · RECRUITING
• Moffitt Cancer Center, Tampa, Florida · RECRUITING
• Piedmont Healthcare, Atlanta, Georgia · RECRUITING
• Mary Bird Perkins Cancer Center, Baton Rouge, Louisiana · RECRUITING
• Johns Hopkins University, Baltimore, Maryland · RECRUITING
• Dana Farber Cancer Institute, Boston, Massachusetts · RECRUITING
• Perlmutter Cancer Center at NYU Langone Health, New York, New York · RECRUITING
• Memorial Sloan-Kettering Cancer Center, New York, New York · RECRUITING
• Columbia University, New York, New York · RECRUITING
• Christ Hospital Cancer Center, Cincinnati, Ohio · RECRUITING
• Taylor Cancer Research Center, Maumee, Ohio · RECRUITING
• Tennessee Oncology, Chattanooga, Tennessee · RECRUITING
• Sarah Cannon Research Institute, Nashville, Tennessee · RECRUITING
• University of Texas at Austin, Austin, Texas · RECRUITING
• Mary Crowley Cancer Research, Dallas, Texas · RECRUITING
• The University of Texas MD Anderson Cancer Center, Houston, Texas · RECRUITING
• Next Oncology, San Antonio, Texas · RECRUITING
• Huntsman Cancer Institute, Salt Lake City, Utah · RECRUITING
• Next Oncology Virginia, Fairfax, Virginia · RECRUITING
• Virginia Mason Medical Center, Seattle, Washington · RECRUITING